Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 449,223 |
|
|||||
| News | - | ||||||
| Day High | 3.00 | Low High |
|||||
| Day Low | 2.651 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Maia Biotechnology Inc | MAIA | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.33 | 12.31% | 3.01 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.70 | 2.651 | 3.00 | 2.94 | 2.68 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,992 | 449,223 | $ 2.85 | $ 1,279,370 | - | 0.82 - 3.07 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 20:00:00 | 1,323 | $ 2.94 | USD |
Maia Biotechnology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 41.22M | 14.21M | - | 0 | -19.77M | -1.39 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Maia Biotechnology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MAIA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.95 | 3.00 | 1.94 | 2.53 | 203,021 | 1.06 | 54.36% |
| 1 Month | 2.21 | 3.00 | 1.851 | 2.41 | 199,453 | 0.80 | 36.20% |
| 3 Months | 1.53 | 3.07 | 1.24 | 2.00 | 333,749 | 1.48 | 96.73% |
| 6 Months | 1.60 | 3.07 | 0.82 | 1.65 | 365,625 | 1.41 | 88.13% |
| 1 Year | 2.30 | 3.07 | 0.82 | 1.78 | 239,390 | 0.71 | 30.87% |
| 3 Years | 4.10 | 9.64 | 0.82 | 3.37 | 228,079 | -1.09 | -26.59% |
| 5 Years | 4.10 | 9.64 | 0.82 | 3.37 | 228,079 | -1.09 | -26.59% |
Maia Biotechnology Description
| MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells. |
